Stay updated on Durvalumab Safety Post Chemo Radiation in Stage III NSCLC Clinical Trial
Sign up to get notified when there's something new on the Durvalumab Safety Post Chemo Radiation in Stage III NSCLC Clinical Trial page.

Latest updates to the Durvalumab Safety Post Chemo Radiation in Stage III NSCLC Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedThe page’s interface revision label was updated from **v3.5.0** to **v3.5.3**, indicating a minor software/version change rather than a change to the clinical trial record itself.SummaryDifference0.1%

- Check53 days agoChange DetectedFooter revision label updated to v3.5.0, replacing the previous v3.4.3.SummaryDifference0.1%

- Check68 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3 in the page history.SummaryDifference0.1%

- Check89 days agoChange DetectedA new revision v3.4.2 was added to the history, replacing the previous v3.4.1.SummaryDifference0.1%

- Check96 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1 in the page history; no visible changes to study details or content.SummaryDifference0.1%

- Check119 days agoChange DetectedAdded Revision: v3.3.4 and removed Revision: v3.3.3 from the page's revision history.SummaryDifference0.1%

Stay in the know with updates to Durvalumab Safety Post Chemo Radiation in Stage III NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab Safety Post Chemo Radiation in Stage III NSCLC Clinical Trial page.